Oncotarget

Research Papers:

Piperlongumine induces apoptosis and reduces bortezomib resistance by inhibiting STAT3 in multiple myeloma cells

Yao Yao, Yueyue Sun, Min Shi, Dandan Xia, Kai Zhao, Lingyu Zeng, Ruosi Yao, Ying Zhang, Zhenyu Li, Mingshan Niu and Kailin Xu _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:73497-73508. https://doi.org/10.18632/oncotarget.11988

Metrics: PDF 2064 views  |   HTML 3052 views  |   ?  


Abstract

Yao Yao1,2,4,*, Yueyue Sun1,2,4,*, Min Shi1,2,4,*, Dandan Xia1,2,4, Kai Zhao1,2,4, Lingyu Zeng1,2,4, Ruosi Yao1,2,4, Ying Zhang3, Zhenyu Li2, Mingshan Niu1,2,4, Kailin Xu1,2,4

1Blood Diseases Institute, Xuzhou Medical College, Xuzhou, Jiangsu, China

2Department of Hematology, The Affiliated Hospital of Xuzhou Medical College, Xuzhou, Jiangsu, China

3Laboratory of Pathology, Xuzhou Medical College, Xuzhou, Jiangsu, China

4Key Laboratory of Bone Marrow Stem Cell, Jiangsu Province, Xuzhou, China

*These authors have contributed equally to this work

Correspondence to:

Kailin Xu, email: [email protected], [email protected]

Mingshan Niu, email: [email protected]

Keywords: multiple myeloma, STAT3, piperlongumine, bortezomib resistance, immunoproteasome

Received: September 17, 2015    Accepted: September 02, 2016    Published: September 13, 2016

ABSTRACT

Effective new therapies are urgently needed for the treatment of multiple myeloma (MM), an incurable hematological malignancy. In this study, we evaluated the effects of piperlongumine on MM cell proliferation both in vivo and in vitro. Piperlongumine inhibited the proliferation of MM cells by inducing cell apoptosis and blocking osteoclastogenesis. Notably, piperlongumine also reduced bortezomib resistance in MM cells. In a disseminated MM mouse model, piperlongumine prolonged the survival of tumor-bearing mice without causing any obvious toxicity. Mechanistically, piperlongumine inhibited the STAT3 signal pathway in MM cells by binding directly to the STAT3 Cys712 residue. These findings suggest that the clinical use of piperlongumine to overcome bortezomib resistance in MM should be evaluated.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 11988